title: [Not Available].
abstract: Tyrosine-kinase inhibitors are recent therapy used in different neoplastic diseases. Dysthyroidism seems to be a class effect of these drugs with a potentially cross cumulative effect. We describe here the case of a man who first developed dysthyroidism with sunitinib, then a deep and permanent hypothyroidism when axitinib was introduced.
authors.affiliation: Centre régional de pharmacovigilance, CHU de Grenoble, Grenoble, France. Electronic address: ckhouri@chu-grenoble.fr.
authors.forename: Charles
authors.initials: C
authors.lastname: Khouri
authors.affiliation: Service pharmacie, Centre hospitalier, Bourg en Bresse, France.
authors.forename: Elodie Jean
authors.initials: EJ
authors.lastname: Bart
authors.affiliation: Centre régional de pharmacovigilance, CHU de Grenoble, Grenoble, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Logerot
authors.affiliation: Service de médecine interne, Centre hospitalier, Villefranchesur-Saône, France.
authors.forename: Amandine
authors.initials: A
authors.lastname: Decker-Bellaton
authors.affiliation: Service pharmacie, Centre hospitalier, Villefranche-sur-Saône, France.
authors.forename: Hervé
authors.initials: H
authors.lastname: Bontemps
authors.affiliation: Centre régional de pharmacovigilance, CHU de Grenoble, Grenoble, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Mallaret
keywords: VEGF; hypothyroidism; hypothyroïdie; inhibiteurs de tyrosine kinases; tyrosine kinase inhibitors